Transfusion-Related Acute Lung Injury

1. Comprehensive Introduction & Overview

Transfusion-Related Acute Lung Injury (TRALI) represents one of the most severe and clinically significant complications associated with blood product transfusion. It is characterized by the sudden onset of non-cardiogenic pulmonary edema occurring during or within six hours of a blood transfusion.

Unlike Transfusion-Associated Circulatory Overload (TACO), which is driven by hydrostatic fluid overload, TRALI is an immunologically mediated or inflammatory process that results in acute lung injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). Despite advancements in blood banking safety, TRALI remains a leading cause of transfusion-related mortality, requiring high clinical suspicion, rapid diagnostic intervention, and supportive critical care management.

The Clinical Significance

TRALI is defined by the development of acute hypoxemia and bilateral pulmonary infiltrates on chest imaging in the absence of left atrial hypertension. Because its clinical presentation often mimics ARDS from other causes, it is frequently underdiagnosed or misattributed to primary cardiac or pulmonary disease.

2. Deep-Dive: Etiology and Pathophysiology

The pathophysiology of TRALI is traditionally described through the "Two-Hit Hypothesis," which explains why only a small subset of patients receiving high-risk plasma products develop the syndrome.

The Two-Hit Hypothesis

1. Hit One (Patient Priming): The patient has an underlying inflammatory state, such as sepsis, recent major surgery, trauma, or active malignancy. This "primes" the pulmonary endothelium and neutrophils, leading to the sequestration of activated neutrophils within the pulmonary microvasculature.
2. Hit Two (Transfusion Trigger): The transfusion of blood products introduces biological response modifiers (BRMs) or antibodies (anti-HLA or anti-HNA) that activate the already primed neutrophils.

Mechanisms of Injury

• Antibody-Mediated TRALI: Donor-derived antibodies (usually IgG) against human leukocyte antigens (HLA) or human neutrophil antigens (HNA) present in the recipient's leukocytes bind to the target antigens. This triggers neutrophil activation, degranulation, and the release of reactive oxygen species (ROS) and proteases, leading to capillary leak.
• Non-Antibody-Mediated TRALI: This involves the infusion of biologically active lipids or cytokines that have accumulated in stored blood components. These substances directly stimulate the endothelial lining of the pulmonary capillaries, increasing vascular permeability.

3. Clinical Staging, Presentation, and Diagnosis

Clinical Presentation

The hallmark of TRALI is a rapid onset of respiratory distress. Symptoms usually manifest within 1–2 hours of the transfusion, though they may occur up to 6 hours post-transfusion.

• Hypoxemia: Defined as a PaO2/FiO2 ratio ≤ 300 mmHg or SpO2 < 90% on room air.
• Fever: Often present, though not universal.
• Hypotension: Frequently observed, which helps distinguish TRALI from TACO (where hypertension is common).
• Cyanosis: A late sign of severe hypoxemia.

Diagnostic Criteria (The "Berlin Definition" Framework)

A diagnosis of TRALI requires the presence of the following:
1. Acute onset: Within 6 hours of transfusion.
2. Hypoxemia: PaO2/FiO2 ≤ 300 mmHg or SpO2 < 90% on room air.
3. Bilateral Infiltrates: Evident on frontal chest radiograph.
4. No evidence of circulatory overload: Absence of left atrial hypertension (e.g., normal BNP or physical exam findings).

Differential Diagnosis

The primary differential for TRALI is TACO. Distinguishing between these two is critical for management.

4. Clinical Indications and Management Strategies

Once TRALI is suspected, management is strictly supportive. There is no specific pharmacological reversal agent.

Immediate Clinical Steps

1. Stop the Transfusion: Immediately discontinue the implicated blood product.
2. Notify the Blood Bank: Initiate a hemovigilance investigation to identify the donor and test for relevant antibodies.
3. Respiratory Support:
   • Initiate supplemental oxygen.
   • If severe, move to non-invasive ventilation (NIV) or mechanical ventilation with lung-protective strategies (low tidal volume 6 mL/kg PBW).
4. Hemodynamic Stabilization: Use judicious fluid resuscitation. Avoid over-hydration, as the lungs are already compromised by capillary leak.
5. Avoid Diuretics: Unless there is clear evidence of co-existing fluid overload, diuretics are generally not indicated and may exacerbate hypotension.

5. Risks, Contraindications, and Prevention

Known Risk Factors

• Plasma-rich products: Fresh Frozen Plasma (FFP) and Platelets pose the highest risk due to the volume of plasma containing antibodies/lipids.
• Multiparity: Female donors who have been pregnant have a higher prevalence of HLA antibodies.
• High-volume transfusions: Increasing the number of units increases the probability of receiving an offending agent.

Preventive Strategies

• Donor Deferral: Avoiding plasma donation from multiparous women or donors with a history of TRALI.
• Male-Only Plasma: Many blood banks now preferentially use plasma from male donors to reduce the incidence of anti-HLA antibodies.
• Leukoreduction: While not a complete preventative, it reduces the total leukocyte load.

6. Massive FAQ Section

1. Is TRALI the same as an allergic reaction?
No. An allergic reaction involves histamine release (hives, itching, anaphylaxis), whereas TRALI is a pulmonary-specific inflammatory injury caused by neutrophil activation.

2. Can TRALI be prevented by pre-medicating with antihistamines?
No. Antihistamines and steroids do not prevent TRALI because the mechanism is not mast-cell degranulation.

3. What is the mortality rate of TRALI?
The reported mortality rate varies between 5% and 20%, depending on the patient's baseline health status and the severity of the respiratory failure.

4. How long does TRALI last?
Most patients show significant clinical improvement within 48 to 96 hours. Unlike ARDS from other causes, TRALI is often self-limiting if the patient survives the initial acute phase.

5. Is TRALI a contraindication to future transfusions?
Not necessarily. The patient is not "allergic" to blood; rather, they received a specific unit that triggered a reaction. However, future transfusions should be handled with extreme caution and only when clinically necessary.

6. Does TRALI require ICU admission?
In almost all cases, yes. TRALI is a life-threatening condition requiring advanced monitoring, blood gas analysis, and potential mechanical ventilation.

7. Can TRALI occur with red blood cell (RBC) transfusions?
Yes. While plasma-rich products carry higher risks, TRALI has been documented with RBC transfusions, likely due to residual plasma or lipid accumulation during storage.

8. What role does BNP play in the diagnosis?
BNP (B-type Natriuretic Peptide) is a crucial biomarker. An elevated BNP strongly suggests TACO (overload) rather than TRALI (non-cardiogenic edema).

9. Are there any long-term lung complications?
Most patients recover with full pulmonary function. However, patients with severe, prolonged TRALI may experience residual pulmonary fibrosis or reduced diffusion capacity in the short term.

10. What should I do if I suspect a TRALI event?
First, stop the transfusion. Second, secure the airway and stabilize hemodynamics. Third, report the event to the hospital’s transfusion medicine service/blood bank immediately to prevent other patients from receiving units from the same donor.

7. Prognosis and Clinical Outlook

The prognosis for TRALI is generally favorable compared to other forms of ARDS, provided that the patient receives timely supportive care. Because the "hit" is a finite event—the transfusion—the inflammatory stimulus is not continuous. As the donor antibodies or lipids are cleared from the recipient's circulation, the pulmonary endothelium typically recovers.

Long-term follow-up studies indicate that the majority of survivors return to their baseline pulmonary status within 30 days. However, the acute phase remains a significant hurdle. Early recognition, avoiding the misdiagnosis of TACO (which would lead to inappropriate fluid restriction or diuretic use), and the implementation of lung-protective ventilation are the pillars of successful management.

Summary of Best Practices for Healthcare Providers

• Maintain a low threshold for suspicion in any patient who develops dyspnea within 6 hours of a transfusion.
• Prioritize blood banking communication. The donor needs to be flagged to ensure safety for the entire blood supply.
• Use conservative fluid management. In the setting of pulmonary permeability, excessive crystalloid administration will worsen the pulmonary edema, even if the patient is not technically in "circulatory overload."

By adhering to these clinical guidelines and maintaining a robust hemovigilance program, medical institutions can significantly mitigate the morbidity and mortality associated with this complex transfusion complication.